Antidepressant medication and executive dysfunction: a deleterious interaction in late-life depression

Area of Science:

• Geriatric psychiatry
• Neuroscience
• Clinical pharmacology

Background:

• Late-life depression is a significant public health concern.
• Deficient response inhibition (DRI) is a cognitive characteristic observed in some older adults.
• Understanding differential treatment responses is crucial for optimizing geriatric depression care.

Purpose of the Study:

• To investigate the differential effects of citalopram versus placebo in older patients with and without deficient response inhibition (DRI).
• To explore potential interactions between cognitive function (DRI) and antidepressant treatment efficacy in late-life depression.

Main Methods:

• An 8-week, double-blind, placebo-controlled trial involving unipolar depressed patients aged 75 years and older.
• Participants received either citalopram (20-40 mg/day) or a placebo pill.
• Cognitive function was assessed using the Stroop Color-Word Test, and depression severity was measured weekly with the Hamilton Rating Scale for Depression.

Main Results:

• Citalopram treatment led to significantly worse outcomes in patients with DRI compared to placebo.
• Conversely, patients without DRI showed significantly better outcomes with citalopram compared to placebo.
• These findings highlight a differential drug response based on the presence of DRI.

Conclusions:

• Older adults with late-life depression and DRI exhibit a poorer response to selective serotonin reuptake inhibitors (SSRIs) compared to placebo.
• The study suggests a potentially deleterious interaction between DRI and antidepressant medication in this population.
• The mechanisms underlying SSRI and placebo response appear to differ in the context of DRI.